NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.Tranilast has a long history of safe use as an oral drug for allergies but there is evidence (widely published in peer reviewed scientific papers) that supports its potential in fibrosis, including IPF.Overall findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated extra-c...
